Nine interdisciplinary projects designed by University of Illinois Urbana-Champaign faculty, including several from the School of Molecular & Cellular Biology, were selected for the Cancer Center at Illinois (CCIL) annual seed grant awards.

Scientists working to understand the cellular processes linking high cholesterol to breast cancer recurrence and metastasis report that a byproduct of cholesterol metabolism causes some cells to send out cancer-promoting signals to other cells. These signals are packaged in membrane-bound...

The liver has a rare superpower among body organs – the ability to regenerate, even if 70% of its mass is removed. It also keeps up its metabolic and toxin-removing work during the process of regeneration, thanks to a subset of cells that expand their workload while the rest focus on multiplication...

Professor Wu was one of ten new faculty hires made in the School of Molecular and Cellular Biology in the last three years. Wu is an assistant professor of and is an affiliate of the Carl R. Woese Institute for Genomic Biology.

Dr. Nelson’s lab focuses on determining how different hormones and metabolite factors impact breast and ovarian cancer progression.

Current cancer treatments include drugs that target standard protein synthesis in cells, which can kill cancer cells, but also targets healthy cells. To address this issue, associate professor of biochemistry and Cancer Center at Illinois (CCIL) member, Hong Jin, is focusing on a non-canonical...

Erik Nelson, professor of molecular and integrative physiology, has won a $4.5 million Era of Hope Scholar Award from the United States Department of Defense Breast Cancer Research Program.This prestigious award supports individuals early in their careers who have demonstrated significant potential...

University of Illinois researchers are leading the science behind a new global licensing agreement between the pharmaceutics company Bayer AG and the cancer drug development company Systems Oncology for a new breast cancer drug called ERSO.

In breast cancer tumors, a molecule produced when the body breaks down cholesterol hijacks the myeloid immune cells that normally arm T cells to fight cancer, a new study in mice found. Instead, the hijacked myeloid cells disarm the T cells and even tell them to self-destruct.

A method known as CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia. It modifies a patient’s own T-cells by adding a piece of an antibody that recognizes unique features on the surface of cancer cells. In a new study, researchers report that they...